Title:
【発明の名称】導入遺伝子の発現持続性を調節するためのトランス活性化およびシス活性化の使用
Document Type and Number:
Japanese Patent JP2002531134
Kind Code:
A
Abstract:
Provided are methods of modulating the persistence of the expression in a cell of a transgene, such as a transgene in a non-Herpes vector or in at least E4DELTA adenoviral vector, and related systems. One method comprises contacting the cell with a non-Herpes vector comprising and expressing a gene encoding HSV ICP0, whereupon expression of HSV ICP0 the persistence of expression of the transgene is modulated. Further provided is a system for modulating the persistence of expression of a transgene, which system comprises a non-Herpes vector comprising (i) a gene encoding HSV ICP0 and (ii) a transgene, wherein the HSV ICP0 modulates the persistence of expression of the transgene and either the non-Herpes vector comprises the transgene or the system further comprises a vector, in which case the vector comprises the transgene. Another method comprises contacting the cell with an at least E4DELTA adenoviral vector comprising (i) a transgene and (ii) a gene encoding a trans-acting factor, wherein the trans-acting factor modulates the persistence of expression of the transgene and the gene encoding the trans-acting factor is not from the E4 region of an adenovirus. Yet another method comprises contacting a cell simultaneously or sequentially with (i) an at least E4DELTA adenoviral vector comprising a transgene and (ii) a viral vector comprising a gene encoding a trans-acting factor, which is not from the E4 region of an adenovirus and which modulates the persistence of expression of the transgene. Also provided is a system for modulating the persistence of expression of a transgene in an at least E4DELTA adenoviral vector, which system comprises (i) an at least E4DELTA adenoviral vector comprising a transgene and (ii) a gene encoding a trans-acting factor, wherein the gene encoding the trans-acting factor is not from the E4 region of an adenovirus, the trans-acting factor modulates the persistence of expression of the transgene, and either the at least E4DELTA adenoviral vector comprises the gene encoding the trans-acting factor or the system comprises a viral vector, in which case the viral vector comprises the gene encoding the trans-acting factor.
More Like This:
Inventors:
Blow, Douglas E.
Kovesdi, Imri
Kovesdi, Imri
Application Number:
JP2000586929A
Publication Date:
September 24, 2002
Filing Date:
December 03, 1999
Export Citation:
Assignee:
Jembek, Incorporated
International Classes:
C12N15/09; A61K35/76; A61K38/00; A61K48/00; A61P31/00; A61P35/00; C07K14/035; C07K14/075; C12N15/35; C12N15/63; C12N15/861; (IPC1-7): C12N15/09; A61K38/00; A61K48/00; A61P31/00; A61P35/00
Attorney, Agent or Firm:
Takashima Hajime